全文获取类型
收费全文 | 108497篇 |
免费 | 7364篇 |
国内免费 | 2730篇 |
专业分类
耳鼻咽喉 | 762篇 |
儿科学 | 1874篇 |
妇产科学 | 3034篇 |
基础医学 | 10459篇 |
口腔科学 | 2049篇 |
临床医学 | 10708篇 |
内科学 | 13165篇 |
皮肤病学 | 801篇 |
神经病学 | 5330篇 |
特种医学 | 3593篇 |
外国民族医学 | 16篇 |
外科学 | 10535篇 |
综合类 | 18467篇 |
现状与发展 | 5篇 |
一般理论 | 5篇 |
预防医学 | 12525篇 |
眼科学 | 1452篇 |
药学 | 10245篇 |
204篇 | |
中国医学 | 9647篇 |
肿瘤学 | 3715篇 |
出版年
2024年 | 226篇 |
2023年 | 1656篇 |
2022年 | 2757篇 |
2021年 | 4418篇 |
2020年 | 4026篇 |
2019年 | 3947篇 |
2018年 | 3626篇 |
2017年 | 3539篇 |
2016年 | 3491篇 |
2015年 | 3212篇 |
2014年 | 6899篇 |
2013年 | 6816篇 |
2012年 | 6262篇 |
2011年 | 7356篇 |
2010年 | 6208篇 |
2009年 | 5062篇 |
2008年 | 4871篇 |
2007年 | 5155篇 |
2006年 | 4529篇 |
2005年 | 3968篇 |
2004年 | 3290篇 |
2003年 | 2955篇 |
2002年 | 2384篇 |
2001年 | 2056篇 |
2000年 | 1724篇 |
1999年 | 1630篇 |
1998年 | 1305篇 |
1997年 | 1286篇 |
1996年 | 1142篇 |
1995年 | 1103篇 |
1994年 | 1046篇 |
1993年 | 786篇 |
1992年 | 801篇 |
1991年 | 711篇 |
1990年 | 622篇 |
1989年 | 589篇 |
1988年 | 564篇 |
1987年 | 459篇 |
1986年 | 410篇 |
1985年 | 703篇 |
1984年 | 659篇 |
1983年 | 493篇 |
1982年 | 573篇 |
1981年 | 532篇 |
1980年 | 505篇 |
1979年 | 454篇 |
1978年 | 387篇 |
1977年 | 346篇 |
1976年 | 275篇 |
1975年 | 202篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
Child benefits are typically paid from birth. This paper asks whether starting universal child benefits in pregnancy leads to improvements in infant health. Leveraging administrative birth registry and hospital microdata from England and Wales, I study the effects of the Health in Pregnancy Grant, a universal conditional cash transfer equivalent to three months of child benefit (190 GBP) as a lump sum to pregnant mothers from 2009 to 2011. I exploit quasi-experimental variation in eligibility with a regression discontinuity design in the date of birth of the baby. I find that the policy increased birth weight by 8–12 grams on average, reduced low birth weight (2500 g) by 3-6 percent and decreased prematurity by 9–11 percent. Younger mothers, particularly those living in deprived areas, benefit the most. I present evidence that the mechanisms are unlikely to be antenatal care, nutrition or smoking, with reductions in stress remaining a possible explanation. 相似文献
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
8.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):94-103.e24
ObjectiveNew-onset postoperative atrial fibrillation (POAF) after cardiac surgery is common, with rates up to 60%. POAF has been associated with early and late stroke, but its association with other cardiovascular outcomes is less known. The objective was to perform a meta-analysis of the studies reporting the association of POAF with perioperative and long-term outcomes in patients with cardiac surgery.MethodsWe performed a systematic review and a meta-analysis of studies that presented outcomes for cardiac surgery on the basis of the presence or absence of POAF. MEDLINE, EMBASE, and the Cochrane Library were assessed; 57 studies (246,340 patients) were selected. Perioperative mortality was the primary outcome. Inverse variance method and random model were performed. Leave-one-out analysis, subgroup analyses, and metaregression were conducted.ResultsPOAF was associated with perioperative mortality (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.58-2.33), perioperative stroke (OR, 2.17; 95% CI, 1.90-2.49), perioperative myocardial infarction (OR, 1.28; 95% CI, 1.06-1.54), perioperative acute renal failure (OR, 2.74; 95% CI, 2.42-3.11), hospital (standardized mean difference, 0.80; 95% CI, 0.53-1.07) and intensive care unit stay (standardized mean difference, 0.55; 95% CI, 0.24-0.86), long-term mortality (incidence rate ratio [IRR], 1.54; 95% CI, 1.40-1.69), long-term stroke (IRR, 1.33; 95% CI, 1.21-1.46), and longstanding persistent atrial fibrillation (IRR, 4.73; 95% CI, 3.36-6.66).ConclusionsThe results suggest that POAF after cardiac surgery is associated with an increased occurrence of most short- and long-term cardiovascular adverse events. However, the causality of this association remains to be established. 相似文献
9.
10.